What is known and objective The coronavirus disease 2019 (COVID‐19) associated
cytokine activation can lead to a rapid progression into respiratory failure, shock and …

Background Due to the lack of proven therapies, we evaluated the effects of early
administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab …

Background Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced
cytokine release syndrome and it may provide clinical benefit for selected COVID–19 …

Background Pneumonia with severe respiratory failure represents the principal cause of
death in COVID-19, where hyper-inflammation plays an important role in lung damage. An …

Background In COVACTA, a randomised, placebo-controlled trial in patients hospitalised
with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day mortality, but …

Background: Tocilizumab may reduce the risk of death, length of stay, and time of
mechanical ventilation in patients hospitalized with COVID-19. Limited data are available …

Objectives Tocilizumab is a humanized monoclonal antibody which targets and inhibits
interleukin-6 (IL-6) and has demonstrated efficacy in treating diseases associated with hyper …

Objective Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19
infections, and cytokine storm is associated with disease severity. Tocilizumab, an …

Background The clinical presentation of SARS-CoV-2 infection ranges from mild symptoms
to severe complications, including acute respiratory distress syndrome. In this syndrome …

Importance Pneumonia due to COVID-19 can lead to respiratory failure and death due to the
development of the acute respiratory distress syndrome. Tocilizumab, a monoclonal …